Friday, May 24, 2019
Category: Immunocompromised Host, Infectious in Oncology
Dr. Kraitman reviews the chronology of cancer treatment history, beginning with the dawn of cancer surgery and progressing through radiation, chemotherapy, immunotherapy, and ultimately, gene therapy. He then explains the basics of Chimeric Antigen Recepter T Cell therapy, a new state of the art therapy utilizing targeted T cells to destroy specific cancer cells. Dr. Kraitman then discusses potential toxicities of CART therapy, including neurotoxicty, Cytokine release syndrome, and HLH, and approaches to manage these adverse effects. Lastly, the speaker discusses infections associated with CAR-T therapy, including bacterial, fungal, and viral pathogens from a clinical series.
Stay in touch! Download our app in the iTunes store or the Google Marketplace.
